Creative Medical Technology Holdings, Inc. (CELZ): History, Ownership, Mission, How It Works & Makes Money

When you look at Creative Medical Technology Holdings, Inc. (CELZ), a clinical-stage biotech, are you seeing a high-risk gamble or the future of regenerative medicine? Honestly, this company is a fascinating case study in platform diversification, having secured an FDA Fast Track Designation in 2025 for its CELZ-201-DDT program targeting the estimated $11 billion annual chronic lower back pain market. They're not just chasing one therapy; their ImmCelz and AlloStem platforms are also tackling the $35 billion Type 1 Diabetes market, a strategy that mitigates the single-product risk typical of the sector. This is a tightly controlled ship, too, with insider ownership sitting at a massive 92.56% as of late 2025, which tells you management is defintely betting on their own science.

Creative Medical Technology Holdings, Inc. (CELZ) History

You're looking for the foundational story of Creative Medical Technology Holdings, Inc., and the core takeaway is this: the company is a classic biotech pivot, moving from an earlier, broader structure to a focused, clinical-stage regenerative medicine platform, culminating in a landmark 2025 with major regulatory and intellectual property wins.

This is a long-game biotech play, not a quick revenue generator yet. The company's trajectory shows a deliberate, decade-plus shift from foundational intellectual property (IP) acquisition to focused, FDA-cleared clinical trials leveraging proprietary cell platforms like AlloStem™ and ImmCelz™.

Given Company's Founding Timeline

Year established

While the initial corporate entity dates back to 1998, the company's current strategic focus on regenerative medicine and its core mission began in 2011. This is when the foundational work for its disruptive cell-based therapies started in earnest.

Original location

The company is headquartered in Phoenix, Arizona, which has served as the base for its corporate operations and strategic direction.

Founding team members

The key driving force behind the current iteration of the company is Timothy Warbington, who serves as the CEO and Co-Founder. His background in finance and operations, spanning over two decades, provided the business structure for translating complex science into a viable pipeline.

Initial capital/funding

Specific initial seed capital is not publicly detailed, but the company has been 'Formerly VC-backed,' indicating early venture capital support. More recently, the company has maintained a lean financial structure, reporting expected cash of approximately $7.5 million with no long-term debt as of June 30, 2024. That's a tight balance sheet for a clinical-stage biotech.

Given Company's Evolution Milestones

Given Company's Transformative Moments

The company's most transformative period has been the aggressive clinical and IP advancement leading up to late 2025. This shows a shift from proof-of-concept to a multi-platform, multi-target strategy.

In terms of financial reality, the trailing twelve-month (TTM) revenue ending September 30, 2025, was only about $6K, which is typical for a clinical-stage biotech. The value is in the pipeline, not current sales. The market capitalization, however, stood at approximately $8.18M as of late October 2025, reflecting the high-risk, high-reward nature of its drug development.

• IP Portfolio Lock-in: In Q3 2025, Creative Medical Technology Holdings secured two cornerstone U.S. patents expanding its ImmCelz coverage to Type 1 Diabetes (expiring 2043) and Heart Failure (expiring 2042). This strategically locks in long-term exclusivity in two of the highest-value global healthcare markets.
• Capital Infusion: The company announced agreements for the exercise of warrants in October 2025, bringing in $4.2 Million in gross proceeds. This is a defintely necessary cash injection to fund ongoing clinical trials like the CELZ-201 (CREATE-1) trial for Type 1 Diabetes.
• Platform Diversification: The company has successfully evolved from single-product focus to advancing multiple platforms-AlloStem™, ImmCelz™, and iPScelz™ (induced pluripotent stem cells). This diversified approach reduces single-product failure risk, which is a smart move in the volatile biotech space.

To understand the strategic intent behind these clinical programs, you should review the company's core principles: Mission Statement, Vision, & Core Values of Creative Medical Technology Holdings, Inc. (CELZ).

Creative Medical Technology Holdings, Inc. (CELZ) Ownership Structure

Creative Medical Technology Holdings, Inc. (CELZ) is a publicly traded, clinical-stage biotechnology company listed on the NASDAQ exchange. The company's ownership structure is heavily weighted toward retail investors, which is common for a small-cap biotech firm still in the clinical development phase.

This structure means the stock is often subject to higher volatility, as retail investors (non-professional traders) tend to trade more frequently than large institutions. As of November 1, 2025, the company had 2,580,532 shares of common stock outstanding.

Creative Medical Technology Holdings, Inc.'s Current Status

The company maintains its status as a publicly traded entity on the NASDAQ Capital Market under the ticker symbol CELZ. This status provides the necessary access to capital markets, which is defintely crucial given the firm's continued operating investment; the nine-month net loss for fiscal year 2025 was approximately $4.11 million.

The low institutional ownership suggests that while the company has attracted some professional money, the majority of the market is still waiting for definitive clinical milestones from its platforms like ImmCelz™ and AlloStem™ before committing significant capital. You can review the strategic direction driving this development in the Mission Statement, Vision, & Core Values of Creative Medical Technology Holdings, Inc. (CELZ).

Creative Medical Technology Holdings, Inc.'s Ownership Breakdown

The company's ownership is dominated by individual, non-professional investors. Here's the quick math on how the shares are distributed as of the latest filings in 2025:

The low institutional float (the percentage of shares available for public trading held by institutions) means that even small trades by a major shareholder can have an outsized impact on the stock price. For example, Armistice Capital, LLC is a notable beneficial owner, with a reported stake of 4.99%.

Creative Medical Technology Holdings, Inc.'s Leadership

The company is steered by a small, experienced leadership team with deep roots in the organization and the regenerative medicine space.

• Timothy Warbington: Co-Founder, Chief Executive Officer (CEO), and President. He has held the CEO role since February 2016 and is the largest individual insider shareholder.
• Donald Dickerson: Senior Vice President. His compensation for the most recent fiscal year was reported at $525,000.
• Michael H. Finger: Independent Director and a minor insider shareholder.
• Susan Snow: Independent Director, with a reported compensation of $120,000.
• Bruce Urdang: Independent Director.

This leadership structure, with the co-founder at the helm, suggests a strategy focused on long-term development of their core proprietary technology platforms, including ImmCelz™ and AlloStem™. The board's average tenure is approximately 4.8 years, indicating a stable and experienced governance body.

Creative Medical Technology Holdings, Inc. (CELZ) Mission and Values

Creative Medical Technology Holdings, Inc. is fundamentally driven by a mission to translate breakthrough regenerative science into tangible, patient-centric therapies, aiming to disrupt multi-billion-dollar healthcare markets like chronic pain and diabetes.

You're investing in a biotech company, so you know the core purpose has to be about more than just a drug; it's about a new paradigm in medicine-Regenerative Medicine 2.0. For Creative Medical, this means leveraging proprietary cell platforms to move beyond symptom management and into true tissue repair and immune system recalibration.

Given Company's Core Purpose

Official mission statement

The company's mission is to develop breakthrough regenerative stem cell therapies across multiple indications to address significant unmet medical needs. This isn't just a boilerplate goal; it's backed by a clear pipeline focused on high-impact areas where current treatments fall short.

• Develop and commercialize regenerative medicine therapies for conditions in immunology, urology, neurology, endocrinology, and orthopedics.
• Evolve from proof-of-concept to clinical trials, a major milestone achieved in 2025.
• Focus on high-value markets, such as the estimated $11 billion annual market for chronic lower back pain and the $35 billion market for Type 1 Diabetes.

Here's the quick math: tackling a fraction of just one of those markets, like the chronic pain segment, could rapidly transform the company's current financial profile, which reported a -$5.49 million loss in 2024.

Vision statement

The vision is to establish Creative Medical as a leader in the new era of regenerative medicine by constructing an Intellectual Property (IP)-fortified franchise. This involves integrating cutting-edge technology to create scalable, patient-centric procedures.

• Position the company as a cornerstone of national medical readiness and veteran health security through its BioDefense Inc. Veterans Initiative.
• Translate Nobel-recognized immunology-specifically regulatory T cell biology-into disruptive treatments that unlock durable value for all stakeholders.
• Build a diversified platform strategy (AlloStem, ImmCelz, iPScelz) that offers multiple shots on goal, de-risking development compared to traditional single-product biotech firms.

To be fair, the company's commitment to innovation is defintely clear in its IP portfolio, which includes over 60 patents and new U.S. patents secured in Q3 2025, providing exclusivity until 2042 and 2043.

Given Company slogan/tagline

While the company does not use a single, formal slogan, its communications consistently highlight a theme of disruptive, multi-platform innovation in cell therapy.

• A Regenerative Medicine and Immunotherapy Company.
• THREE PLATFORMS. ONE DISRUPTIVE ENGINE.
• Pioneering regenerative immunotherapy.

The core values are evident in the operational focus: Innovation (integrating AI into its iPScelz platform), Scalability (manufacturing over 6 billion clinical-grade AlloStem cells), and Financial Discipline (securing $4.2 million in working capital from warrant exercises in October 2025). You can explore more about their Mission Statement, Vision, & Core Values of Creative Medical Technology Holdings, Inc. (CELZ).

Creative Medical Technology Holdings, Inc. (CELZ) How It Works

Creative Medical Technology Holdings, Inc. operates as a clinical-stage biotechnology company, focused on pioneering regenerative immunotherapy by developing proprietary, cell-based therapies to address significant unmet medical needs in large, multi-billion-dollar markets like chronic pain and autoimmune disease.

The company's value creation is centered on advancing its three distinct cellular platforms-AlloStem™, ImmCelz™, and iPScelz™-through FDA-cleared clinical trials, moving from proof-of-concept to scalable, commercial-ready treatments that target the root cause of disease, not just the symptoms.

Creative Medical Technology Holdings, Inc.'s Product/Service Portfolio

Creative Medical Technology Holdings, Inc.'s Operational Framework

You're looking at a lean, clinical-stage biotech that prioritizes platform scalability and financial discipline, which is defintely smart given the high cost of drug development.

• Manufacturing Scale: The company has already manufactured over 6 billion clinical-grade AlloStem cells under cGMP (Current Good Manufacturing Practice), meaning the core technology is ready to scale immediately for multiple indications.
• Clinical Advancement: Operations are focused on accelerating the two pivotal, FDA-cleared clinical programs, CELZ-201-DDT and CELZ-201, which are the near-term value catalysts.
• Capital Management: Financial operations are strategically directed toward high-return milestones. For example, in October 2025, the company announced agreements for the exercise of warrants, securing $4.2 million in gross proceeds to fund working capital and general corporate purposes.
• Technology Integration: The operational process includes integrating Artificial Intelligence (AI) into platforms like iPScelz™ to decode cellular behavior, which drives the development of more precise, personalized regenerative medicine treatments.

Here's the quick math: The company's revenue for the trailing 12 months ending March 31, 2025, was only $14.00 thousand, showing its current focus is on R&D and clinical milestones, not commercial sales yet, and that's reflected in the consensus fiscal year 2025 EPS forecast of -$2.03.

Creative Medical Technology Holdings, Inc.'s Strategic Advantages

The core advantage isn't a single drug; it's the diversified, multi-platform approach, which gives them a much better risk profile than most single-product biotech firms.

• Platform Diversification: The three distinct platforms-AlloStem, ImmCelz, and iPScelz-provide 'multiple shots on goal' across vast therapeutic areas (orthopedics, endocrinology, cardiology), which inherently de-risks the development pipeline.
• Intellectual Property Fortress: The company holds a robust IP portfolio of over 60 patents and pending applications. The cornerstone patents secured in Q3 2025 for ImmCelz in Type 1 Diabetes and Heart Failure lock in market exclusivity until 2043 and 2042, respectively.
• Regulatory Validation: Securing FDA Fast Track Designation for CELZ-201-DDT for chronic lower back pain accelerates the development timeline and allows for rolling Biologics License Application (BLA) submissions, potentially expediting market access.
• Scientific Alignment: Their patented biology aligns with mechanisms recognized by the 2025 Nobel Prize® in Physiology or Medicine for foundational discoveries in regulatory T cell (Treg) biology, lending significant third-party credibility to their ImmCelz platform.

If you want a deeper dive into who is betting on this strategy, you should read Exploring Creative Medical Technology Holdings, Inc. (CELZ) Investor Profile: Who's Buying and Why?

Creative Medical Technology Holdings, Inc. (CELZ) How It Makes Money

Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company, meaning its primary financial engine is currently not product sales but rather capital raises and intellectual property development. The company generates minimal revenue from the sale of stem cell treatments, but its core value lies in advancing its regenerative medicine platforms-AlloStem™, ImmCelz™, and iPScelz™-through clinical trials to secure future commercialization or licensing deals.

Creative Medical Technology Holdings, Inc.'s Revenue Breakdown

As of the nine months ended September 30, 2025, the company's revenue remains extremely low, reflecting its pre-commercial stage focus on research and development (R&D). Total sales for this period were only $0.003 million (or $3,000). This minimal revenue is derived from a single activity, which we categorize as Stem Cell Treatments, though it is not a commercially scalable product yet.

To be fair, a clinical-stage biotech company's revenue table often looks like this. The decreasing trend is based on the nine-month sales of $3,000 in 2025, down from $8,000 in the same period a year ago. The real financial opportunity is in the future commercialization of its platforms, not in current sales.

Business Economics

The company operates on a high fixed-cost, low-variable-revenue model typical of early-stage biotech, where the focus is on intellectual property (IP) and clinical validation, not profit. This is defintely a long-term play.

• Primary Value Driver: The core economic asset is the company's IP portfolio, which includes over 60 patents and pending applications protecting its three proprietary platforms.
• Cost Structure: Costs are overwhelmingly driven by R&D expenses and General and Administrative (G&A) overhead to support clinical trials and regulatory compliance, such as the FDA-cleared trials for chronic lower back pain and new-onset Type 1 Diabetes.
• Pricing Strategy: A formal, commercial pricing strategy is not yet in place, as the therapies are still in clinical development. Future pricing for successful therapies like AlloStem™ will likely be premium, reflecting the high cost of development and the significant clinical value in multi-billion-dollar markets like Type 1 Diabetes.
• Funding Mechanism: Since revenue is negligible, the company's operations are sustained almost entirely by equity financing. For example, the company raised approximately $3.7 million and $3.8 million in net proceeds from warrant exercises in March and October 2025, respectively.

You're investing in the science and the patents, not the current cash flow. For more on the long-term vision, you can review the Mission Statement, Vision, & Core Values of Creative Medical Technology Holdings, Inc. (CELZ).

Creative Medical Technology Holdings, Inc.'s Financial Performance

The financial health of Creative Medical Technology Holdings, Inc. must be viewed through the lens of a developmental-stage company, where losses are expected and capital preservation is key.

• Net Loss: For the nine months ended September 30, 2025, the company reported a net loss of $4.11 million, an increase from $3.64 million in the prior year period. This widening loss reflects continued investment in R&D and clinical programs.
• Cash Position: As of September 30, 2025, the company maintained a cash balance of $5.38 million. This cash, plus the $3.8 million raised in October 2025, provides the runway to fund operations deeper into 2026.
• Loss Per Share (LPS): The diluted loss per share from continuing operations for the nine months ended September 30, 2025, was $1.72.
• Path to Profitability: Analysts project the company may incur a final loss in 2026 before potentially generating positive profits of $16 million in 2027. Here's the quick math: achieving this breakeven by 2027 requires an aggressive average annual revenue growth rate of about 62%.

What this estimate hides is the binary risk of biotech: success in a clinical trial could trigger a massive revenue inflection, but failure means the capital is burned. The low debt-to-equity ratio (debt is only about 0.2% of equity) is a positive, showing prudent capital management by relying on equity funding rather than debt.

Creative Medical Technology Holdings, Inc. (CELZ) Market Position & Future Outlook

Creative Medical Technology Holdings, Inc. (CELZ) is a clinical-stage biotechnology company with a minimal commercial footprint, but it holds a strong pipeline of proprietary, off-the-shelf cell therapy platforms aimed at multi-billion-dollar markets. The company's future trajectory is entirely dependent on positive clinical data from its two pivotal FDA-cleared programs, with key readouts anticipated in 2026.

You're looking at a high-risk, high-reward biotech play where the current valuation is tied to intellectual property (IP) and clinical milestones, not current revenue. For the nine months ended September 30, 2025, the company reported a net loss of $4.11 million against minimal revenue, so all focus must be on the pipeline catalysts.

Competitive Landscape

Creative Medical Technology Holdings operates in the highly fragmented and rapidly expanding regenerative medicine market, which is estimated to be worth $37.98 billion in 2025. Its current market share is negligible, but its competitive edge lies in its allogeneic (universal donor) platform approach, which is designed to be more scalable than patient-specific therapies.

Opportunities & Challenges

The company has clear opportunities in two massive therapeutic areas, but its financial structure presents a constant challenge. The path to profitability requires an aggressive average annual growth rate of 62% to hit the analyst-projected breakeven in 2027. [cite: 10 in step 1]

Industry Position

Creative Medical Technology Holdings is best positioned as an innovative, clinical-stage disruptor within the allogeneic (universal donor) stem cell therapy segment. It is not competing on commercial revenue, but on the potential of its technology.

• The company's strategy of advancing three distinct platforms-AlloStem, ImmCelz, and iPScelz-across multiple indications is designed to de-risk its pipeline, offering multiple shots on goal unlike many single-product biotechs. [cite: 6 in step 1]
• Its focus on orthopedics (chronic lower back pain) aligns with the largest application area in the regenerative medicine market, which commanded approximately 33.40% of the total revenue share in 2025. [cite: 7 in step 2]
• The integration of Artificial Intelligence (AI) into the iPScelz platform is a forward-looking move to enhance the precision and efficiency of cell line development. [cite: 15 in step 1]
• Despite the minimal revenue, the company's liquidity is maintained by recent capital raises, with cash and short-term investments at $5.38 million as of September 30, 2025. [cite: 8 in step 1]

You should view Creative Medical Technology Holdings as a pure play on regenerative medicine technology, where the next 12-18 months of clinical data will be the primary determinant of its value. Exploring Creative Medical Technology Holdings, Inc. (CELZ) Investor Profile: Who's Buying and Why?